Yahoo
LSE - Delayed Quote GBp

Bioventix PLC (BVXP.L)

2,007.10 +7.10 (+0.35%)
As of 2:19:13 PM GMT. Market Open.
Chart Range Bar
Loading chart for BVXP.L
  • Previous Close 2,000.00
  • Open 2,000.00
  • Bid 2,000.00 x --
  • Ask 2,100.00 x --
  • Day's Range 1,950.00 - 2,120.00
  • 52 Week Range 1,300.00 - 2,255.00
  • Volume 10,642
  • Avg. Volume 13,855
  • Market Cap (intraday) 104.868M
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 13.94
  • EPS (TTM) 1.44
  • Earnings Date --
  • Forward Dividend & Yield 1.50 (7.50%)
  • Ex-Dividend Date Apr 9, 2026
  • 1y Target Est 3,900.00

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

www.bioventix.com

12

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

BVXP.L
5.40%
FTSE 100 (^FTSE)
7.95%

1-Year Return

BVXP.L
2.02%
FTSE 100 (^FTSE)
10.33%

3-Year Return

BVXP.L
44.54%
FTSE 100 (^FTSE)
43.98%

5-Year Return

BVXP.L
44.89%
FTSE 100 (^FTSE)
47.38%

Analyst Insights

View More

Analyst Price Targets

3,900.00
3,900.00 Average
2,007.10 Current
3,900.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    58.70%

  • Return on Assets (ttm)

    48.78%

  • Return on Equity (ttm)

    66.31%

  • Revenue (ttm)

    12.97M

  • Net Income Avi to Common (ttm)

    7.61M

  • Diluted EPS (ttm)

    1.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.26M

  • Total Debt/Equity (mrq)

    0.03%

  • Levered Free Cash Flow (ttm)

    6.67M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: